JP2015514780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514780A5 JP2015514780A5 JP2015507204A JP2015507204A JP2015514780A5 JP 2015514780 A5 JP2015514780 A5 JP 2015514780A5 JP 2015507204 A JP2015507204 A JP 2015507204A JP 2015507204 A JP2015507204 A JP 2015507204A JP 2015514780 A5 JP2015514780 A5 JP 2015514780A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- alkyl
- tetrahydro
- aryl
- isoindol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 18
- -1 bromo, hydroxyl Chemical group 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 208000017169 kidney disease Diseases 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 201000009030 Carcinoma Diseases 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 201000008383 nephritis Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000004253 NUT midline carcinoma Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002346 iodo group Chemical group I* 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- KTKRIGLYOPUJHW-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-3,6,6-trimethyl-5,7-dihydro-2h-isoindol-4-one Chemical compound C1=C2OCOC2=CC(C=2NC(=C3C(=O)CC(C)(C)CC3=2)C)=C1 KTKRIGLYOPUJHW-UHFFFAOYSA-N 0.000 claims 1
- IWSOERZTQGUJBE-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C1=C2OCOC2=CC(C=2NC(=C3C(=O)CCCC3=2)C)=C1 IWSOERZTQGUJBE-UHFFFAOYSA-N 0.000 claims 1
- JZCJXICMFMLUJZ-UHFFFAOYSA-N 1-(1h-benzimidazol-4-yl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC2=C1N=CN2 JZCJXICMFMLUJZ-UHFFFAOYSA-N 0.000 claims 1
- YOTIPHWJHFCAHM-UHFFFAOYSA-N 1-(1h-indol-4-yl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC2=C1C=CN2 YOTIPHWJHFCAHM-UHFFFAOYSA-N 0.000 claims 1
- PNFXBCAHIYXNCS-UHFFFAOYSA-N 1-(1h-indol-7-yl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC2=C1NC=C2 PNFXBCAHIYXNCS-UHFFFAOYSA-N 0.000 claims 1
- XWHDXODHBWZBOT-UHFFFAOYSA-N 1-(2,5-dimethylphenyl)-3,6,6-trimethyl-5,7-dihydro-2h-isoindol-4-one Chemical compound C=12CC(C)(C)CC(=O)C2=C(C)NC=1C1=CC(C)=CC=C1C XWHDXODHBWZBOT-UHFFFAOYSA-N 0.000 claims 1
- IPQGUMYPDJKXTB-UHFFFAOYSA-N 1-(2-aminophenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1N IPQGUMYPDJKXTB-UHFFFAOYSA-N 0.000 claims 1
- KFQQPTLDTFBRQK-UHFFFAOYSA-N 1-(2-chlorophenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1Cl KFQQPTLDTFBRQK-UHFFFAOYSA-N 0.000 claims 1
- ATNQVJPFWABKDU-UHFFFAOYSA-N 1-(2-hydroxyphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1O ATNQVJPFWABKDU-UHFFFAOYSA-N 0.000 claims 1
- QZOYGSGPQBSZDX-UHFFFAOYSA-N 1-(2-methoxyphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound COC1=CC=CC=C1C1=C(CCCC2=O)C2=C(C)N1 QZOYGSGPQBSZDX-UHFFFAOYSA-N 0.000 claims 1
- ZFIVCUMQHABKGM-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=C(C)C(C)=C1 ZFIVCUMQHABKGM-UHFFFAOYSA-N 0.000 claims 1
- GSXPSDSZKQUFLI-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(C)=CC(C)=C1 GSXPSDSZKQUFLI-UHFFFAOYSA-N 0.000 claims 1
- IATNVYSUJGABAI-UHFFFAOYSA-N 1-(3-methoxyphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound COC1=CC=CC(C2=C3C(C(CCC3)=O)=C(C)N2)=C1 IATNVYSUJGABAI-UHFFFAOYSA-N 0.000 claims 1
- HNBNCLQGZIXKGD-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=C(Cl)C=C1 HNBNCLQGZIXKGD-UHFFFAOYSA-N 0.000 claims 1
- HRWQXKQANTYRCN-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(CCCC2=O)C2=C(C)N1 HRWQXKQANTYRCN-UHFFFAOYSA-N 0.000 claims 1
- DRAZPLJDOFGOIK-UHFFFAOYSA-N 1-(4-methylsulfonylphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound CS(=O)(=O)c1ccc(cc1)-c1[nH]cc2c1CCCC2=O DRAZPLJDOFGOIK-UHFFFAOYSA-N 0.000 claims 1
- KYAWXAUITZHJRN-UHFFFAOYSA-N 1-(5-amino-2-phenoxyphenyl)-3,6-dimethyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound N1C(C)=C2C(=O)CC(C)CC2=C1C1=CC(N)=CC=C1OC1=CC=CC=C1 KYAWXAUITZHJRN-UHFFFAOYSA-N 0.000 claims 1
- WEJMCQNBCYFALA-UHFFFAOYSA-N 1-(5-amino-2-phenoxyphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(N)=CC=C1OC1=CC=CC=C1 WEJMCQNBCYFALA-UHFFFAOYSA-N 0.000 claims 1
- BGSQOSGWZRPTLA-UHFFFAOYSA-N 1-(5-amino-2-phenylsulfanylphenyl)-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(N)=CC=C1SC1=CC=CC=C1 BGSQOSGWZRPTLA-UHFFFAOYSA-N 0.000 claims 1
- ONATZLYGADHBJA-UHFFFAOYSA-N 1-[2-(1-benzothiophen-7-ylmethoxy)phenyl]-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1=CC=CC2=C1SC=C2 ONATZLYGADHBJA-UHFFFAOYSA-N 0.000 claims 1
- YMCHEABHBGZVDX-UHFFFAOYSA-N 1-[2-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-ylmethoxy)phenyl]-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound Cc1[nH]c(c2CCCC(=O)c12)-c1ccccc1OCC1CCC2NNCC2C1 YMCHEABHBGZVDX-UHFFFAOYSA-N 0.000 claims 1
- WMYVPEGLLFWXFC-UHFFFAOYSA-N 1-[2-(cyclopentylmethoxy)phenyl]-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1CCCC1 WMYVPEGLLFWXFC-UHFFFAOYSA-N 0.000 claims 1
- GYIIQSPBAWRRNV-UHFFFAOYSA-N 1-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(S(C)(=O)=O)=CC=C1OCC1CC1 GYIIQSPBAWRRNV-UHFFFAOYSA-N 0.000 claims 1
- GQOVPCCOVGDBIY-UHFFFAOYSA-N 1-[2-(furan-2-yl)phenyl]-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1C1=CC=CO1 GQOVPCCOVGDBIY-UHFFFAOYSA-N 0.000 claims 1
- DUSZXFWSVYJAOF-UHFFFAOYSA-N 1-[5-amino-2-(2,4-difluorophenoxy)phenyl]-3-methyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(N)=CC=C1OC1=CC=C(F)C=C1F DUSZXFWSVYJAOF-UHFFFAOYSA-N 0.000 claims 1
- NTXWWEVXMMKHEZ-UHFFFAOYSA-N 2-[[2-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)phenyl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC=CC=C1C1=C(CCCC2=O)C2=C(C)N1 NTXWWEVXMMKHEZ-UHFFFAOYSA-N 0.000 claims 1
- ACVFVWRQUIKXGY-UHFFFAOYSA-N 3,6,6-trimethyl-1-(2-morpholin-4-ylphenyl)-5,7-dihydro-2h-isoindol-4-one Chemical compound C=12CC(C)(C)CC(=O)C2=C(C)NC=1C1=CC=CC=C1N1CCOCC1 ACVFVWRQUIKXGY-UHFFFAOYSA-N 0.000 claims 1
- SHSSQWGTZJDXJE-UHFFFAOYSA-N 3,6,6-trimethyl-1-(2-phenoxyphenyl)-5,7-dihydro-2h-isoindol-4-one Chemical compound C=12CC(C)(C)CC(=O)C2=C(C)NC=1C1=CC=CC=C1OC1=CC=CC=C1 SHSSQWGTZJDXJE-UHFFFAOYSA-N 0.000 claims 1
- KPLWFVHCDJNLEY-UHFFFAOYSA-N 3,6,6-trimethyl-1-(2-phenylmethoxyphenyl)-5,7-dihydro-2h-isoindol-4-one Chemical compound C=12CC(C)(C)CC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1=CC=CC=C1 KPLWFVHCDJNLEY-UHFFFAOYSA-N 0.000 claims 1
- UNKBHMZQVRQKMT-UHFFFAOYSA-N 3,6,6-trimethyl-1-phenyl-5,7-dihydro-2h-isoindol-4-one Chemical compound C=12CC(C)(C)CC(=O)C2=C(C)NC=1C1=CC=CC=C1 UNKBHMZQVRQKMT-UHFFFAOYSA-N 0.000 claims 1
- CJTIYLJHCHNPMW-UHFFFAOYSA-N 3,6-dimethyl-1-(2-phenoxyphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound N1C(C)=C2C(=O)CC(C)CC2=C1C1=CC=CC=C1OC1=CC=CC=C1 CJTIYLJHCHNPMW-UHFFFAOYSA-N 0.000 claims 1
- JGAPUDSHJKIBTJ-UHFFFAOYSA-N 3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxy-n-(1,3-thiazol-2-yl)benzamide Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(C(=O)NC=2SC=CN=2)=CC=C1OC1=CC=CC=C1 JGAPUDSHJKIBTJ-UHFFFAOYSA-N 0.000 claims 1
- WVDPOAIKYQWDOZ-UHFFFAOYSA-N 3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxybenzoic acid Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(C(O)=O)=CC=C1OC1=CC=CC=C1 WVDPOAIKYQWDOZ-UHFFFAOYSA-N 0.000 claims 1
- CTBWYTRBGFAKKX-UHFFFAOYSA-N 3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-n-(oxolan-2-ylmethyl)-4-phenoxybenzamide Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(C(=O)NCC2OCCC2)=CC=C1OC1=CC=CC=C1 CTBWYTRBGFAKKX-UHFFFAOYSA-N 0.000 claims 1
- DFNGNBXFVXAOCM-UHFFFAOYSA-N 3-(4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)benzamide Chemical compound NC(=O)c1cccc(c1)-c1[nH]cc2c1CCCC2=O DFNGNBXFVXAOCM-UHFFFAOYSA-N 0.000 claims 1
- WRXGMFLVIUSNDK-UHFFFAOYSA-N 3-[2-(2,4-difluorophenoxy)-5-(dimethylsulfamoylamino)phenyl]-1-methyl-7-oxo-2,4,5,6-tetrahydroisoindole Chemical compound N1C(C)=C(C(CCC2)=O)C2=C1C1=CC(NS(=O)(=O)N(C)C)=CC=C1OC1=CC=C(F)C=C1F WRXGMFLVIUSNDK-UHFFFAOYSA-N 0.000 claims 1
- KLYIVVNLQIHWNI-UHFFFAOYSA-N 3-methyl-1-(2-phenoxyphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OC1=CC=CC=C1 KLYIVVNLQIHWNI-UHFFFAOYSA-N 0.000 claims 1
- VNWIMYPGWYDJDP-UHFFFAOYSA-N 3-methyl-1-(2-phenoxyphenyl)-6-propan-2-yl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound N1C(C)=C2C(=O)CC(C(C)C)CC2=C1C1=CC=CC=C1OC1=CC=CC=C1 VNWIMYPGWYDJDP-UHFFFAOYSA-N 0.000 claims 1
- PAOLRTCRMCYGGK-UHFFFAOYSA-N 3-methyl-1-(2-phenylmethoxyphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1=CC=CC=C1 PAOLRTCRMCYGGK-UHFFFAOYSA-N 0.000 claims 1
- QAVZHJBPFKNTBV-UHFFFAOYSA-N 3-methyl-1-(3,4,5-trimethoxyphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound COC1=C(OC)C(OC)=CC(C2=C3C(C(CCC3)=O)=C(C)N2)=C1 QAVZHJBPFKNTBV-UHFFFAOYSA-N 0.000 claims 1
- ZCRMXBAXVISRIW-UHFFFAOYSA-N 3-methyl-1-(3-phenylmethoxyphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C(C=1)=CC=CC=1OCC1=CC=CC=C1 ZCRMXBAXVISRIW-UHFFFAOYSA-N 0.000 claims 1
- KYPZUGNTMFFUGV-UHFFFAOYSA-N 3-methyl-1-(4-methylphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=C(C)C=C1 KYPZUGNTMFFUGV-UHFFFAOYSA-N 0.000 claims 1
- SRFWHJITEQCFKW-UHFFFAOYSA-N 3-methyl-1-[2-(2-morpholin-4-ylethoxy)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCCN1CCOCC1 SRFWHJITEQCFKW-UHFFFAOYSA-N 0.000 claims 1
- ZGXNSYXRSQHEEM-UHFFFAOYSA-N 3-methyl-1-[2-(oxan-4-ylmethoxy)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1CCOCC1 ZGXNSYXRSQHEEM-UHFFFAOYSA-N 0.000 claims 1
- ISLIDDIUISDJBK-UHFFFAOYSA-N 3-methyl-1-[2-(oxolan-2-ylmethoxy)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1CCCO1 ISLIDDIUISDJBK-UHFFFAOYSA-N 0.000 claims 1
- FFCIGHPMQLSGQS-UHFFFAOYSA-N 3-methyl-1-[2-(oxolan-3-ylmethoxy)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1CCOC1 FFCIGHPMQLSGQS-UHFFFAOYSA-N 0.000 claims 1
- ISGFWRVRBVLULL-UHFFFAOYSA-N 3-methyl-1-[2-(phenoxymethyl)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1COC1=CC=CC=C1 ISGFWRVRBVLULL-UHFFFAOYSA-N 0.000 claims 1
- KNAYLNPPQZHTRM-UHFFFAOYSA-N 3-methyl-1-[2-(pyridin-2-ylmethoxy)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1=CC=CC=N1 KNAYLNPPQZHTRM-UHFFFAOYSA-N 0.000 claims 1
- MRUGCFKSMMOJMA-UHFFFAOYSA-N 3-methyl-1-[2-(pyridin-3-ylmethoxy)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1OCC1=CC=CN=C1 MRUGCFKSMMOJMA-UHFFFAOYSA-N 0.000 claims 1
- GVLVEXRNIGZXQG-UHFFFAOYSA-N 3-methyl-1-[2-(quinolin-8-ylmethoxy)phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C1=CN=C2C(COC3=CC=CC=C3C=3NC(=C4C(=O)CCCC4=3)C)=CC=CC2=C1 GVLVEXRNIGZXQG-UHFFFAOYSA-N 0.000 claims 1
- JSMVNMJPTVARQR-UHFFFAOYSA-N 3-methyl-1-[2-[(2-methylphenoxy)methyl]phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1COC1=CC=CC=C1C JSMVNMJPTVARQR-UHFFFAOYSA-N 0.000 claims 1
- XHJYEPAONLSFRZ-UHFFFAOYSA-N 3-methyl-1-[2-[[3-(trifluoromethyl)phenoxy]methyl]phenyl]-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1COC1=CC=CC(C(F)(F)F)=C1 XHJYEPAONLSFRZ-UHFFFAOYSA-N 0.000 claims 1
- WDQNILVOGXOEAK-UHFFFAOYSA-N 3-methyl-1-naphthalen-1-yl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C1=CC=C2C(C=3NC(=C4C(=O)CCCC4=3)C)=CC=CC2=C1 WDQNILVOGXOEAK-UHFFFAOYSA-N 0.000 claims 1
- YSRFOFRGKIZHIW-UHFFFAOYSA-N 3-methyl-1-phenyl-2,5,6,7-tetrahydroisoindol-4-one Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=CC=C1 YSRFOFRGKIZHIW-UHFFFAOYSA-N 0.000 claims 1
- PYDJAYNMHQETSJ-UHFFFAOYSA-N 3-methyl-6-(2-methylpropyl)-1-(2-phenoxyphenyl)-2,5,6,7-tetrahydroisoindol-4-one Chemical compound N1C(C)=C2C(=O)CC(CC(C)C)CC2=C1C1=CC=CC=C1OC1=CC=CC=C1 PYDJAYNMHQETSJ-UHFFFAOYSA-N 0.000 claims 1
- BGLDFYUDXWBVGT-UHFFFAOYSA-N 4-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)benzenesulfonamide Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC=C(S(N)(=O)=O)C=C1 BGLDFYUDXWBVGT-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010054949 Metaplasia Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- HDMMJYDNLMDGQT-UHFFFAOYSA-N N-[4-(2,4-difluorophenoxy)-3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)phenyl]pyrrolidine-2-carboxamide Chemical compound Cc1[nH]c(c2CCCC(=O)c12)-c1cc(NC(=O)C2CCCN2)ccc1Oc1ccc(F)cc1F HDMMJYDNLMDGQT-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010070863 Toxicity to various agents Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 201000011186 acute T cell leukemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 208000019748 bullous skin disease Diseases 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000002409 gliosarcoma Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000015689 metaplastic ossification Effects 0.000 claims 1
- NPKQOBAGAPKRFP-UHFFFAOYSA-N methyl 3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxybenzoate Chemical compound N1C(C)=C(C(CCC2)=O)C2=C1C1=CC(C(=O)OC)=CC=C1OC1=CC=CC=C1 NPKQOBAGAPKRFP-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000005987 myeloid sarcoma Diseases 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- MLLITSKIYPDIGG-UHFFFAOYSA-N n-[3-(2,3-dimethyl-4-oxo-6,7-dihydro-5h-isoindol-1-yl)-4-phenoxyphenyl]acetamide Chemical compound C=12CCCC(=O)C2=C(C)N(C)C=1C1=CC(NC(=O)C)=CC=C1OC1=CC=CC=C1 MLLITSKIYPDIGG-UHFFFAOYSA-N 0.000 claims 1
- IPNOJAZMRYGFBZ-UHFFFAOYSA-N n-[3-(2,3-dimethyl-4-oxo-6,7-dihydro-5h-isoindol-1-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound CN1C(C)=C(C(CCC2)=O)C2=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 IPNOJAZMRYGFBZ-UHFFFAOYSA-N 0.000 claims 1
- FXDDTMBJHBDSRS-UHFFFAOYSA-N n-[3-(3,6,6-trimethyl-4-oxo-5,7-dihydro-2h-isoindol-1-yl)phenyl]methanesulfonamide Chemical compound C=12CC(C)(C)CC(=O)C2=C(C)NC=1C1=CC=CC(NS(C)(=O)=O)=C1 FXDDTMBJHBDSRS-UHFFFAOYSA-N 0.000 claims 1
- BHKRQVDASRVKHJ-UHFFFAOYSA-N n-[3-(3,6-dimethyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound N1C(C)=C2C(=O)CC(C)CC2=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 BHKRQVDASRVKHJ-UHFFFAOYSA-N 0.000 claims 1
- GZFJPALDEYOFHA-UHFFFAOYSA-N n-[3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 GZFJPALDEYOFHA-UHFFFAOYSA-N 0.000 claims 1
- QWTIBECCMDOFQM-UHFFFAOYSA-N n-[3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenylsulfanylphenyl]methanesulfonamide Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(NS(C)(=O)=O)=CC=C1SC1=CC=CC=C1 QWTIBECCMDOFQM-UHFFFAOYSA-N 0.000 claims 1
- KKHATMJRKUVXCG-UHFFFAOYSA-N n-[3-(3-methyl-4-oxo-6-phenyl-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound C1C(=O)C2=C(C)NC(C=3C(=CC=C(NS(C)(=O)=O)C=3)OC=3C=CC=CC=3)=C2CC1C1=CC=CC=C1 KKHATMJRKUVXCG-UHFFFAOYSA-N 0.000 claims 1
- BAUAWADOZHNVKK-UHFFFAOYSA-N n-[3-(3-methyl-4-oxo-6-propan-2-yl-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound N1C(C)=C2C(=O)CC(C(C)C)CC2=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 BAUAWADOZHNVKK-UHFFFAOYSA-N 0.000 claims 1
- IJHLQXVFYDYMNK-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)phenyl]acetamide Chemical compound N1C(C)=C(C(CCC2)=O)C2=C1C1=CC(NC(=O)C)=CC=C1OC1=CC=C(F)C=C1F IJHLQXVFYDYMNK-UHFFFAOYSA-N 0.000 claims 1
- IJLMGCMNZFELBZ-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)phenyl]ethanesulfonamide Chemical compound N1C(C)=C(C(CCC2)=O)C2=C1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F IJLMGCMNZFELBZ-UHFFFAOYSA-N 0.000 claims 1
- PLXPCRHHULAZDG-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)phenyl]methanesulfonamide Chemical compound C=12CCCC(=O)C2=C(C)NC=1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F PLXPCRHHULAZDG-UHFFFAOYSA-N 0.000 claims 1
- WUXWTHNWHPQNIS-UHFFFAOYSA-N n-[4-(4,4-difluorocyclohexyl)oxy-3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)phenyl]ethanesulfonamide Chemical compound N1C(C)=C(C(CCC2)=O)C2=C1C1=CC(NS(=O)(=O)CC)=CC=C1OC1CCC(F)(F)CC1 WUXWTHNWHPQNIS-UHFFFAOYSA-N 0.000 claims 1
- UYVKPTPDSHKJCN-UHFFFAOYSA-N n-ethyl-3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxybenzamide Chemical compound N1C(C)=C(C(CCC2)=O)C2=C1C1=CC(C(=O)NCC)=CC=C1OC1=CC=CC=C1 UYVKPTPDSHKJCN-UHFFFAOYSA-N 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 238000013146 percutaneous coronary intervention Methods 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 1
- 201000008753 synovium neoplasm Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2012/074411 | 2012-04-20 | ||
| PCT/CN2012/074411 WO2013155695A1 (en) | 2012-04-20 | 2012-04-20 | Isoindolone derivatives |
| US13/796,731 US9776990B2 (en) | 2012-04-20 | 2013-03-12 | Isoindolone derivatives |
| US13/796,731 | 2013-03-12 | ||
| PCT/US2013/037297 WO2013158952A1 (en) | 2012-04-20 | 2013-04-19 | Isoindolone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514780A JP2015514780A (ja) | 2015-05-21 |
| JP2015514780A5 true JP2015514780A5 (enExample) | 2016-06-16 |
Family
ID=49380677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015506064A Expired - Fee Related JP5989229B2 (ja) | 2012-04-20 | 2012-04-20 | イソインドロン誘導体 |
| JP2015507204A Pending JP2015514780A (ja) | 2012-04-20 | 2013-04-19 | イソインドロン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015506064A Expired - Fee Related JP5989229B2 (ja) | 2012-04-20 | 2012-04-20 | イソインドロン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9776990B2 (enExample) |
| EP (2) | EP2838881B1 (enExample) |
| JP (2) | JP5989229B2 (enExample) |
| CN (1) | CN104334526A (enExample) |
| CA (2) | CA2870931A1 (enExample) |
| HK (1) | HK1206744A1 (enExample) |
| MX (2) | MX2014012635A (enExample) |
| WO (2) | WO2013155695A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| CA2870931A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
| SG11201505979UA (en) | 2013-02-19 | 2015-09-29 | Bayer Pharma AG | Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines |
| EP2958922A1 (de) | 2013-02-22 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
| WO2014128111A1 (de) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituierte pyrrolo- und pyrazolo-diazepine |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| EP3412675A1 (en) | 2013-05-27 | 2018-12-12 | Novartis AG | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| AU2014272700B2 (en) | 2013-05-28 | 2016-12-01 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| EA029269B1 (ru) | 2013-11-21 | 2018-02-28 | Новартис Аг | Производные пирролопирролона и их применение для лечения заболеваний |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2015131005A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| JP2018522871A (ja) * | 2015-07-02 | 2018-08-16 | オリオン コーポレーション | ブロモドメイン阻害剤としての二環式複素環誘導体 |
| TW201718514A (zh) * | 2015-08-07 | 2017-06-01 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經２－（雜）芳基取代之稠合雜環衍生物 |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| US11548899B2 (en) | 2016-02-15 | 2023-01-10 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| KR20180132861A (ko) | 2016-04-12 | 2018-12-12 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bet 단백질 분해제 |
| PT3442972T (pt) | 2016-04-15 | 2020-05-29 | Abbvie Inc | Inibidores de bromodomínio |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| CA3036834A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| CA3036841A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
| CN108069959A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
| WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| WO2019055444A1 (en) | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS |
| EP3898587B1 (en) * | 2018-12-21 | 2024-06-26 | Albert-Ludwigs-Universität Freiburg | Condensed pyrroles as novel bromodomain inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| DE69631347T2 (de) | 1995-09-15 | 2004-10-07 | Upjohn Co | Aminoaryl oxazolidinone n-oxide |
| EP0912548A1 (en) * | 1996-07-11 | 1999-05-06 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
| JP3455230B2 (ja) * | 1996-07-11 | 2003-10-14 | ファイザー製薬株式会社 | インターロイキン―およびｔｎｆアンタゴニストとして有用なピリジルピロール化合物 |
| CN1109037C (zh) | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并－三唑并二氮杂䓬化合物及其医药用途 |
| PT853083E (pt) * | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| FR2771412B1 (fr) * | 1997-11-26 | 2000-04-28 | Adir | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6083969A (en) * | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
| CN1297916A (zh) | 1999-11-26 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸 |
| CN1315397A (zh) | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸 |
| US7223733B2 (en) | 2004-03-31 | 2007-05-29 | National University Of Singapore | Modulation of TRIP-Br function and method of treating proliferative disorders |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| WO2006008754A1 (en) | 2004-07-20 | 2006-01-26 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| WO2008024978A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| AU2008242703B2 (en) | 2007-04-19 | 2011-08-18 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009015180A2 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2217548A1 (en) | 2007-10-26 | 2010-08-18 | Concert Pharmaceuticals Inc. | Deuterated darunavir |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AU2010314395B2 (en) | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| EP3050885B1 (en) | 2009-11-05 | 2017-10-18 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| CA2870931A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
-
2012
- 2012-04-20 CA CA 2870931 patent/CA2870931A1/en not_active Abandoned
- 2012-04-20 HK HK15107457.4A patent/HK1206744A1/xx unknown
- 2012-04-20 WO PCT/CN2012/074411 patent/WO2013155695A1/en not_active Ceased
- 2012-04-20 MX MX2014012635A patent/MX2014012635A/es unknown
- 2012-04-20 JP JP2015506064A patent/JP5989229B2/ja not_active Expired - Fee Related
- 2012-04-20 EP EP12874480.2A patent/EP2838881B1/en not_active Not-in-force
- 2012-04-20 CN CN201280073829.3A patent/CN104334526A/zh active Pending
-
2013
- 2013-03-12 US US13/796,731 patent/US9776990B2/en not_active Expired - Fee Related
- 2013-04-19 EP EP13719348.8A patent/EP2850071A1/en not_active Withdrawn
- 2013-04-19 WO PCT/US2013/037297 patent/WO2013158952A1/en not_active Ceased
- 2013-04-19 JP JP2015507204A patent/JP2015514780A/ja active Pending
- 2013-04-19 MX MX2014012695A patent/MX2014012695A/es unknown
- 2013-04-19 US US14/395,628 patent/US20150111890A1/en not_active Abandoned
- 2013-04-19 CA CA 2870446 patent/CA2870446A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514780A5 (enExample) | ||
| JP2019511482A5 (enExample) | ||
| RU2018140061A (ru) | Ингибиторы бромодомена | |
| RU2014131378A (ru) | Ингибиторы бромдомена | |
| RU2015143192A (ru) | Тетрациклические ингибиторы бромодоменов | |
| RU2015143191A (ru) | Дигидропирролопиридиновые ингибиторы бромодоменов | |
| JP6227707B2 (ja) | Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 | |
| RU2019142795A (ru) | Производное n-(азаарил)циклолактам-1-карбоксамида, метод его получения и его применение | |
| JP2009534407A5 (enExample) | ||
| JP2019516757A5 (enExample) | ||
| SI2956452T1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2018519323A5 (enExample) | ||
| NZ630875A (en) | Heterocyclic compounds and uses thereof | |
| JP2017533248A5 (enExample) | ||
| HRP20171154T1 (hr) | Kristalni inhibitori bromodomene | |
| JP2017533250A5 (enExample) | ||
| RU2014141674A (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| JP2012532112A5 (enExample) | ||
| JP2017510642A5 (enExample) | ||
| RU2020131507A (ru) | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции | |
| JP2010540602A5 (enExample) | ||
| RU2011134868A (ru) | N-замещенные насыщенные гетероциклические сульфоновые соединения с активностью агонистов рецептора св2 | |
| JP2016507581A5 (enExample) | ||
| JP6355645B2 (ja) | 活性成分としてテトラゾール誘導体を含む、溶解性が改善された固体分散体 | |
| ES2811849T3 (es) | Pomada |